50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Sell every Stock except ONE (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
'A Gold Storm Is Coming' (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
'A Gold Storm Is Coming' (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Sell every Stock except ONE (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
'A Gold Storm Is Coming' (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
'A Gold Storm Is Coming' (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Sell every Stock except ONE (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
'A Gold Storm Is Coming' (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
'A Gold Storm Is Coming' (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
Sell every Stock except ONE (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
'A Gold Storm Is Coming' (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
'A Gold Storm Is Coming' (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
NASDAQ:GMAB

Genmab A/S - GMAB Stock Forecast, Price & News

$31.82
+0.30 (+0.95%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$31.43
$32.28
50-Day Range
$31.52
$37.70
52-Week Range
$26.19
$47.28
Volume
554,263 shs
Average Volume
627,404 shs
Market Capitalization
$20.94 billion
P/E Ratio
35.36
Dividend Yield
N/A
Price Target
$37.15

Genmab A/S MarketRank™ Forecast

Analyst Rating
Hold
2.10 Rating Score
Upside/​Downside
1,621.0% Upside
$547.62 Price Target
Short Interest
Bearish
0.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Genmab A/S in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
19.61%
From $1.02 to $1.22 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

479th out of 1,071 stocks

Pharmaceutical Preparations Industry

219th out of 531 stocks

GMAB stock logo

About Genmab A/S (NASDAQ:GMAB) Stock

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GMAB Stock News Headlines

GMAB : Should Expect Sideways To Lower Before Upside Resumes
NASDAQ:GMAB (Genmab A/S)
Genmab Improves Its 2022 Financial Guidance
Genmab: A Royalty Powerhouse With A Strong Pipeline
Where Genmab Stands With Analysts
Genmab A/S Q1 2022 Earnings Preview
See More Headlines
Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GMAB Company Calendar

Last Earnings
8/10/2022
Today
9/27/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMAB
Fax
N/A
Employees
1,212
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$547.62
High Stock Price Forecast
$3,100.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+16.7%
Consensus Rating
Hold
Rating Score (0-4)
2.10
Research Coverage
10 Analysts

Profitability

Net Income
$478.57 million
Pretax Margin
50.78%

Debt

Sales & Book Value

Annual Sales
$1.35 billion
Cash Flow
$0.79 per share
Book Value
$5.37 per share

Miscellaneous

Free Float
647,974,000
Market Cap
$20.94 billion
Optionable
Not Optionable
Beta
0.85

Social Links


Key Executives

  • Dr. Jan G.J. van de Winkel Ph.D. (Age 61)
    Co-Founder, Pres & CEO
    Comp: $2.41M
  • Mr. Anthony Pagano (Age 44)
    Exec. VP & CFO
    Comp: $716.85k
  • Mr. Anthony Mancini (Age 51)
    Exec. VP & COO
    Comp: $1.3M
  • Dr. Judith V. Klimovsky M.D. (Age 64)
    Exec. VP & Chief Devel. Officer
    Comp: $909.85k
  • Dr. Tahamtan Ahmadi (Age 49)
    Exec. VP, Chief Medical Officer & Head of Experimental Medicines
    Comp: $744.42k
  • Dr. Mijke Zachariasse Ph.D. (Age 48)
    Director of Protein Production & Chemist and Non-Independent Director
    Comp: $124.07k
  • Dr. Rima Bawarshi Nassar Ph.D. (Age 69)
    VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director
    Comp: $110.28k
  • Mr. Peter Ros
    Sr. Director of Fin. & Accounting
  • Mr. Andrew Carlsen
    Sr. Director, VP & Head of Investor Relations
  • Ms. Birgitte Stephensen M.Sc. (Age 61)
    Exec. VP & Chief Legal Officer













GMAB Stock - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings
or view top-rated stocks.

What is Genmab A/S's stock price forecast for 2022?

10 Wall Street analysts have issued 1-year price targets for Genmab A/S's stock. Their GMAB share price forecasts range from $31.00 to $3,100.00. On average, they predict the company's stock price to reach $547.62 in the next twelve months. This suggests a possible upside of 1,621.0% from the stock's current price.
View analysts price targets for GMAB
or view top-rated stocks among Wall Street analysts.

How have GMAB shares performed in 2022?

Genmab A/S's stock was trading at $39.56 at the beginning of the year. Since then, GMAB shares have decreased by 19.6% and is now trading at $31.82.
View the best growth stocks for 2022 here
.

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our GMAB earnings forecast
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) released its quarterly earnings results on Wednesday, August, 10th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.21 by $0.20. The company earned $452.86 million during the quarter, compared to analyst estimates of $435.40 million. Genmab A/S had a net margin of 38.42% and a trailing twelve-month return on equity of 17.12%.

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S updated its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.72 billion-$1.86 billion.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

When did Genmab A/S IPO?

(GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

What is Genmab A/S's stock symbol?

Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB."

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Macquarie Group Ltd. (0.54%), Artisan Partners Limited Partnership (0.22%), Renaissance Technologies LLC (0.15%), Hardman Johnston Global Advisors LLC (0.14%), Wells Fargo & Company MN (0.10%) and Federated Hermes Inc. (0.09%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genmab A/S's stock price today?

One share of GMAB stock can currently be purchased for approximately $31.82.

How much money does Genmab A/S make?

Genmab A/S (NASDAQ:GMAB) has a market capitalization of $20.94 billion and generates $1.35 billion in revenue each year. The company earns $478.57 million in net income (profit) each year or $0.90 on an earnings per share basis.

How many employees does Genmab A/S have?

The company employs 1,212 workers across the globe.

How can I contact Genmab A/S?

Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728 or via email at acn@genmab.com.

This page (NASDAQ:GMAB) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.